We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The device will help eliminate the waiting period experienced by approximately 70 percent of patients that would normally need a custom stent graft, the company said. Read More
“Patients who test positive for a deleterious BRCA mutation will be eligible to receive advanced medical management, such as prophylactic surgery or targeted therapies,” the company said. Read More